ASH 2023 | Quantifying biomarkers on lambda amyloidogenic light chains to diagnose AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, speaks on a groundbreaking diagnostic test for light chain (AL) amyloidosis, which was presented at ASH 2023. This quantitative assessment focuses on a neo-epitope on the lambda amyloidogenic light chain, effectively distinguishing lambda AL amyloidosis from other conditions. The test has clinical utility in screening patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SM) for AL amyloidosis. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Alexion: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Prothena: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Regeneron: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
